The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy

Expert Rev Anticancer Ther. 2020 Mar;20(3):147-150. doi: 10.1080/14737140.2020.1732212. Epub 2020 Feb 24.

Authors

Pedro Barata¹, Umang Swami², Neeraj Agarwal²

Affiliations

¹ Tulane University, New Orleans, LA, USA.
² Huntsman Cancer Institute, University of Utah, Salt Lake, UT, USA.

PMID: 32068456
DOI: 10.1080/14737140.2020.1732212

No abstract available

Keywords: Metastatic castration-sensitive prostate cancer; androgen axis inhibitors; apalutamide; phase III.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Androgen Antagonists / administration & dosage
Androgen Receptor Antagonists / administration & dosage
Animals
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Humans
Male
Neoplasm Metastasis
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / pathology
Thiohydantoins / administration & dosage*

Substances

Androgen Antagonists
Androgen Receptor Antagonists
Thiohydantoins
apalutamide